

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**Inhibition of human respiratory syncytial virus infectivity by a dendrimeric heparan sulfate-binding peptide.**

**This is the author's manuscript**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/123703> since 2017-05-16T16:28:13Z

*Published version:*

DOI:10.1128/AAC.00771-12

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



# UNIVERSITÀ DEGLI STUDI DI TORINO

*This is an author version of the contribution published on:*

*Antimicrob Agents Chemother. 2012 Oct;56(10):5278-88.*

*doi: 10.1128/AAC.00771-12.*

*The definitive version is available at:*

*<http://aac.asm.org/>*



1 **Abstract**

2 Respiratory syncytial virus (RSV) interacts with cell surface heparan sulphate proteoglycans  
3 (HSPGs) to initiate infection. The interaction of RSV with HSPGs thus presents an attractive target  
4 for the development of novel inhibitors of RSV infection. In the present study, a minilibrary of  
5 linear, dimeric and dendrimeric peptides containing clusters of basic amino acids was screened with  
6 the aim of identifying peptides able to bind HSPGs and thus block RSV attachment and infectivity.  
7 Of the hit compounds identified, the dendrimer SB105-A10 was the most potent inhibitor of RSV  
8 infectivity, with IC<sub>50</sub> values equal to 0.35 μM and 0.25 μM measured in Hep-2 and A549 cells,  
9 respectively. SB105-A10 was found to bind to both cell types via HSPGs, suggesting that its  
10 antiviral activity was indeed exerted by competing with RSV for binding to cell-surface HSPGs.  
11 SB105-A10 prevented RSV infection when added before the viral inoculum, in line with its  
12 proposed HSPG-binding mechanism of action; moreover, antiviral activity was also exhibited when  
13 added post-infection, being able to reduce the cell-to-cell spread of the virus. The antiviral potential  
14 of SB105-A10 was further assessed using human-derived tracheal/bronchial epithelial cells cultured  
15 to form a pseudo-stratified, highly differentiated model of the epithelial tissue of the human  
16 respiratory tract. SB105-A10 strongly reduced RSV infectivity in this model and presented no signs  
17 of cytotoxicity or pro-inflammatory effects. Together, these features render SB105-A10 an  
18 attractive candidate for further development as a RSV inhibitor to be administered by aerosol  
19 delivery.

20

21

1 **Introduction.**

2  
3 Human respiratory syncytial virus (RSV) is an enveloped RNA virus which belongs to the  
4 *Pneumovirus* genus of the *Paramyxoviridae* family (6). It is the leading cause of lower respiratory  
5 tract infections, such as bronchiolitis and pneumonia, in infants and young children worldwide. The  
6 risk factors for severe RSV disease include premature birth, low birth weight, bronchopulmonary  
7 displasia, congenital heart disease, immunodeficiency and the timing of birth in relation to the  
8 winter season (32, 50). As RSV infection does not produce any long lasting immunity, recurrent  
9 infections may occur throughout life, although they are milder in healthy children and adults. RSV  
10 causes severe morbidity and mortality in the elderly, particularly in those with chronic obstructive  
11 pulmonary disease (14). In the United States alone, as many as 120,000 hospitalisations and 200-  
12 500 deaths occur annually as a result of RSV infections in infants and young children; and as many  
13 as 160,000 fatalities occur worldwide (27, 39, 49). The hospitalisation of RSV patients in the  
14 United States produces an annual economic burden of approximately \$500 million, and  
15 considerable further costs should be added to this figure in relation to outpatient care (18, 33). The  
16 management of RSV infection is primarily symptomatic (8) and any antiviral treatment is limited to  
17 the use of ribavirin, a drug with controversial activity and associated with significant side effects  
18 (11, 42, 47). Palivizumab, a humanised monoclonal antibody, has been approved for the  
19 immunoprophylaxis of RSV infection in just one narrowly defined patient group: high-risk  
20 prematurely born infants (23, 51). However, a major problem with palivizumab is its high costs,  
21 which may lead to the progressive restriction of its use (8, 41). Motavizumab, an affinity-matured  
22 variant of palivizumab, was expected to replace palivizumab for the prevention of RSV infection in  
23 infants, however it was recently denied approval by the FDA on the basis of concerns about safety  
24 and allergic reactions.

25 No vaccine for RSV is currently available. Previous vaccine attempts failed to elicit a long-lasting  
26 protective immune response (4) and the approval of a new RSV vaccine is not expected before  
27 2020. This scenario makes RSV an important target for antiviral research and development (42).

1 Recently developed drugs under investigation as therapeutic agents against RSV were recently  
2 reviewed (48).

3 While ample evidence demonstrates the binding of RSV to cultured cells to involve an interaction  
4 between the viral envelope glycoproteins G and F and cell surface heparan sulphate proteoglycans  
5 (HSPGs), as well as other sulphated proteoglycans (3, 13, 15, 16, 19, 21, 24, 26, 31, 44),  
6 compelling evidence recently identified the cellular protein nucleolin as a specific receptor for RSV  
7 (43). The authors propose that RSV binds to cell surface proteoglycans to allow the RSV fusion  
8 protein to interact with nucleolin. The interactions between RSV and cell surface HSPGs required  
9 for RSV attachment and entry into host cells therefore represent a valid target for the inhibition of  
10 RSV infectivity.

11 HSPGs consist of a core protein bearing glycosaminoglycan (GAGs) chains composed of  
12 unbranched heparan sulphate (HS) chains, which are structurally related to heparin (1). On the  
13 molecular level, the negatively charged sulphated/carboxyl groups of HSPGs/heparin (20) interact  
14 with a cluster of positively charged basic amino acids present within the linear heparin binding  
15 domain (HBD) of RSV glycoprotein G (16). Interestingly, a similar putative HBD was also  
16 identified in RSV glycoprotein F (15), suggesting that the HSPG-HBD interaction is a common  
17 theme in the RSV proteins that mediate infection, making it a preferential target for the  
18 development of antiviral compounds against RSV.

19 Sulphated polysaccharides are a large, heterogeneous group of charged polymers that are able to  
20 mimic HS chains and thereby interact with viral glycoproteins and block virus attachment to HSPGs  
21 by competitive inhibition (36, 37). Sulphated polysaccharides have been extensively studied as  
22 broad range antiviral compounds and some of them [e.g. heparin (20), chondroitin sulphate (19) and  
23 dextran sulphate (25)] have proved to be active against RSV.

24 In principle, a second type of inhibitors could be designed that act through the opposite mechanism:  
25 i.e. molecules that inhibit virus attachment by masking the host cell RSV binding sites. For  
26 example, polycationic molecules able to bind to HSPGs would mask these receptors from the virus,

1 thereby preventing its attachment to the cell surface. The feasibility of this alternative anti-viral  
2 strategy is sustained by two observations: a) basic fibroblast growth factor (bFGF) and protamine,  
3 two prototypic heparin-binding molecules, reduce RSV infection by binding to HSPGs (19); and b)  
4 linear heparin-binding peptides derived from RSV F glycoprotein inhibit RSV infectivity (9). Little  
5 research attention has been placed onto the development of antivirals that act via this latter  
6 mechanism in comparison with that placed on the use of sulphated polysaccharides. The reason is  
7 most likely due to the fact that cell surface HSPG molecules are expressed at a concentration of  $10^5$ -  
8  $10^6$  molecule/cell, and each molecule bears several saccharidic chains endowed with multiple  
9 binding sites. Thus, the amount of HSPG-binding required to inhibit virus attachment is much  
10 higher than that required when the binding sites on the virus itself are targeted.

11 Dendrimers have recently come to the limelight as attractive potential new therapeutics due to their  
12 multivalency and consequent capacity to interact with biological recognition processes (5).  
13 Accordingly, dendrimers have been studied as antiviral drugs endowed with multiple binding sites  
14 that can efficiently prevent/disrupt the molecular interactions mediating cell attachment and hence  
15 virus infection (2). Indeed, HSPG-binding dendrimers have successfully been found to inhibit the  
16 infection of human papillomaviruses (HPV), human cytomegalovirus (HCMV) and herpes simplex  
17 virus (HSV) (10, 28, 29). Antiviral dendrimeric peptides consist of a lysine peptidyl branching core  
18 and four covalently attached surface peptide functional units, containing clusters of basic amino  
19 acids that bind to the negatively charged sulphate and carboxyl groups of HS.

20 The aim of the present work was to screen a minilibrary of linear, dimeric and dendrimeric peptides  
21 for their RSV-antagonist activity and to investigate the antiviral potency, the mode of action and the  
22 biocompatibility of the best hit compound. The HSPG-binding peptide dendrimer SB105-A10  
23 emerged as a potent inhibitor of RSV infectivity both in cell culture and in a model of human-  
24 derived tracheal/bronchial epithelium.

25

## 1 MATERIALS AND METHODS

### 2 Cells and viruses.

3 The epithelial cell lines Hep-2 (ATCC CCL-23) and A549 (ATCC CCL-185) were grown as  
4 monolayers in Eagle's minimal essential medium (MEM) (Gibco/BRL, Gaithersburg, MD)  
5 supplemented with heat-inactivated 10% foetal calf serum (FCS) (Gibco/BRL). RSV strain A2  
6 (ATCC VR-1540) was propagated in Hep-2 cells by infecting a freshly prepared confluent  
7 monolayer grown in MEM supplemented with 2% of FCS. When the cytopathic effect involved the  
8 whole monolayer, the infected cell suspension was collected and the clarified viral supernatant then  
9 adjusted to 100 mM MgSO<sub>4</sub> and 50 mM Tris-HCl (pH 7.5) to stabilise the viruses as previously  
10 reported (17). The virus stocks were aliquoted and stored at -80°C. The infectivity of virus stocks  
11 was determined on Hep-2 cell monolayers and calculated using the Reed-Muench method; titres are  
12 reported as 50% tissue culture infectious doses (TCID<sub>50</sub>) (22).

13 The cell lines and the RSV were obtained from the American Type Culture Collection (Manassas,  
14 VA, USA).

15 **Reagents.** Heparin (13.6 kDa) was obtained from Laboratori Derivati Organici Spa (Milan, Italy).  
16 Heparinase III, a glycosidase that digests the glycosaminoglycan moiety of HSPGs (12), was  
17 obtained from Sigma-Aldrich (St. Louis, MO, USA).

18 **Antiviral compound minilibrary.** The potential antiviral compounds were synthesised as peptides  
19 in tetrameric, dimeric or linear forms, as described previously (10).

20 **Cell viability assay.** Cells were seeded at a density of  $5 \times 10^4$ /well in 24-well plates and treated the  
21 next day with serially diluted peptidic compounds to generate dose-response curves. After 48 or 72  
22 hours of incubation, cell viability was determined using the CellTiter 96 Proliferation Assay Kit  
23 (Promega, Madison, WI, USA), according to the manufacturer's instructions. Absorbances were  
24 measured using a Microplate Reader (Model 680, BIORAD) at 490 nm. 50% cytotoxic  
25 concentration (CC<sub>50</sub>) values and 95% confidence intervals (CIs) were determined using Prism  
26 software (GraphPad Software, San Diego, CA).



1 **Infectivity inhibition assay.** To assay the antiviral activity of the linear dimeric, and dendrimeric  
2 peptides, the compounds were diluted to a concentration of 33 µg/ml (for minilibrary screening) or  
3 serially diluted (for further characterisation) and added to cells grown as monolayers in a 96-well  
4 plate. After 45 minutes of incubation at 4°C, virus (diluted to yield 20 to 40 plaques/well in 100 µl)  
5 was added to linear or dendrimeric peptide-treated and untreated control wells and allowed to  
6 adsorb for 3 hours at room temperature; the monolayers were then washed and overlaid with 1.2%  
7 methylcellulose medium. Three days post-infection, cells were fixed with cold methanol and  
8 acetone for 1 minute and subjected to RSV-specific immunostaining using an RSV monoclonal  
9 antibody (Ab35958, Abcam, Cambridge, UK) and the UltraTech HRP streptavidin-biotin detection  
10 system (Beckman Coulter, Marseille, France). Immunostained plaques were counted and the  
11 percent inhibition of virus infectivity determined by comparing the number of plaques in linear or  
12 dendrimeric peptide-treated wells with the number in untreated control wells. 50% inhibitory  
13 concentration (IC50) values and 95% CIs were determined using Prism software. All data were  
14 generated from duplicate wells in at least three independent experiments.

15 **Syncytium formation assay.** The ability of the dendrimeric peptide SB105A10 to block RSV cell-  
16 to-cell spread was evaluated using a previously described method (30) with minor modifications.  
17 Cell monolayers in 96-well plates were infected with RSV in MEM supplemented with 2% FCS for  
18 3 hours at room temperature, then subjected to two gentle washes to remove unbound virus.  
19 Increasing concentrations of the dendrimeric peptide SB105A10 in 1.2% methylcellulose medium  
20 were then added to cultures after washout of the inoculum. Incubation continued for 72 hours post-  
21 infection at 37°C; cells were then fixed and immunostained. The immunostained syncytia were  
22 visualised using a Leica inverted Microscope equipped with a Bresser MikroCam microscope  
23 camera and MikroCamLab software (Rhede, Germany). ImageJ software was used to quantify  
24 plaque sizes. Untreated RSV-infected monolayers were used as the control.

25 **Cell pretreatment assay.** Hep-2 cell monolayers in 96-well plates were incubated with increasing  
26 concentrations of the dendrimeric peptide SB105-A10 for one hour at 4°C. After removal of the

1 compound and two gentle washes, cells were infected with RSV according to the protocol described  
2 above for the infectivity inhibition assays (except for the absence of compounds during the  
3 infection). Cells were then overlaid with 1.2% methylcellulose medium, incubated for 3 days at  
4 37°C and successively fixed and immunostained as described above. Plaques were then counted.

5 **Attachment assay.** Various concentrations of the dendrimeric peptide SB105-A10 were  
6 preincubated with RSV for 1 hour at 4°C. The mixture was added to cooled Hep-2 cells in 96-well  
7 plates and incubated for 2 hours at 4°C to ensure viral attachment but not entry. After two gentle  
8 washes, cells were overlaid with 1.2% methylcellulose medium, shifted to 37°C for 72 hours and  
9 successively fixed and immunostained as described above. Plaques were then counted.

10 **Binding assay.** The dendrimeric peptide SB105-A10 or heparin (100 µg/ml) was added to the  
11 aliquot of RSV ( $10^4$  PFU), incubated for 1 hour at 4°C, added to Hep-2 cell monolayers in DMEM  
12 supplemented with 2% FCS, further incubated for 2 hours at 4°C and finally washed two times to  
13 remove unbound virus. Cells were fixed with 4% paraformaldehyde, air dried and blocked with 5%  
14 BSA in PBS-Tween. Bound virus was detected using the RSV monoclonal antibody (diluted 1:200)  
15 incubated for 1 hour at room temperature, washed three times with PBS-Tween and incubated for 2  
16 hours at 37°C with goat anti-mouse IgG conjugated to horseradish peroxidase (1:1000). At the end  
17 of incubation, plates were washed three times with PBS-Tween before adding ABTS substrate  
18 (Thermo scientific, Rockford) and reading the absorbance at 655 nm. Percent inhibition of virus  
19 binding was determined by comparing the absorbance measured in the presence of the dendrimeric  
20 peptide SB105-A10 to that measured in untreated wells.

21 **Cell-binding assay for SB105-A10-PEG-biotin peptide:** Monolayers of A549 and Hep2 cells in  
22 96-well plates were incubated for 2 hours at 4° C in phosphate buffered saline (PBS) containing 0.1  
23 mg/ml CaCl<sub>2</sub>, 0.1 mg/ml MgCl<sub>2</sub> and 0.1 % gelatin and: i) increasing concentrations of SB105-A10-  
24 PEG-biotin peptide; or ii) a fixed amount (220 nM) of SB105-A10-PEG-biotin peptide in the  
25 absence or presence of heparin (100 µg/ml); or iii) SB105-A10-PEG-biotin peptide (220 ng/ml)  
26 alone, then washed with PBS containing 2 M NaCl – a treatment known to remove cationic

1 polypeptides from cell surface HSPGs (35); or iv) pre-incubated for 48 h at 37°C with DMEM  
2 containing 40 mM sodium chlorate to abrogate GAG sulphation (38); or v) pre-incubated for 1 h at  
3 37°C with heparinase III (15 mU/ml) before proceeding with the binding assay.

4 At the end of incubations, cells were washed with PBS and the amount of cell associated SB105-  
5 A10-PEG-biotin peptide determined with horseradish peroxidase-labelled streptavidin (1/5,000) and  
6 the chromogen substrate ABTS (Kierkegaard & Perry Laboratories, Gathersburg, MA).

7 **EpiAirway™ tissues.** EpiAirway™ tissues, cultured on collagen supports under air-liquid interface  
8 conditions, were obtained from MatTek Corp. (Ashland, MA, USA). These tissues consisted of  
9 normal human-derived tracheal/bronchial epithelial cells that are highly differentiated (i.e., contain  
10 cilia, tight junctions, sodium and chloride channels, etc.) and retain properties of normal respiratory  
11 tract epithelial tissue (i.e., actively secrete mucus, electrogenicity, etc.). EpiAirway™ tissues have  
12 an average trans epithelial electric resistance (TEER) of  $391.2 \pm 50.2 \Omega/\text{cm}^2$ . Upon delivery, the  
13 tissue inserts were processed according to the supplier's protocol. Briefly, each tissue insert was  
14 transferred to a well in a 6-well plate pre-filled with 900 ml pre-warmed serum free media (AIR-  
15 100-MM, MatTek Corp.) and incubated at 37 °C in 5% CO<sub>2</sub> overnight (16-18 h).

16 **Evaluation of SB105A10 cellular toxicity in EpiAirway™ tissues.** The cytotoxicity of the  
17 dendrimeric peptide SB105A10 on mucous membranes was performed using the MatTek  
18 EpiAirway™ System and the MTT ET-50 Tissue Viability Assay followed by the analysis of  
19 lactate dehydrogenase (LDH) levels, according to the manufacturer's instructions.

20 SB105A10 (100 µg/ml) was added to the cell culture insert on top of the EpiAirway™ tissue  
21 samples and incubated for 0.5, 1, 4, or 18 hours in duplicate. At the end of incubation, any liquid  
22 on top of the EpiAirway™ tissue was decanted and inserts were gently rinsed with PBS to remove  
23 any residual material. Then, tissues were processed according to the MTT kit protocol (MatTek  
24 Corporation) and read using an ELISA plate reader at a wavelength of 570 nm. Tissues incubated  
25 with ultrapure water were used as the negative control. 1.0% Triton X-100 was used as the positive  
26 control. The ET-50 value refers to the time required to reduce tissue viability to 50% and was

1 determined using Prism software (GraphPad Software, San Diego, CA, USA). To analyse the  
2 release of lactate dehydrogenase from the treated EpiAirway™ tissues into the culture medium, the  
3 LDH Cytotoxicity Detection Kit (TAKARA bio inc, Japan) was used, following the manufacturer's  
4 protocol.

5 **Analysis of inflammatory response.** To evaluate the inflammatory response, EpiAirway™ tissues  
6 were treated with the dendrimeric peptide SB105A10 (100 µg/ml) for different exposure times of  
7 0.5, 1, 4, and 18 hours, as reported previously. After incubation, the concentration of interleukin 8  
8 (IL-8) in culture medium was measured according to the instructions provided by the manufacturer  
9 using an IL-8 ELISA assay kit from ImmunoTools (Friesoythe, Germany). The concentration of IL-  
10 8 was calculated by interpolation of a standard calibration curve.

11 **Antiviral assay in EpiAirway™ Tissue.** EpiAirway™ cultures were pre-incubated with  
12 SB105A10 by applying 100 µl of medium containing 100 µg/ml of the compound to the apical  
13 surface and incubating for 2 hours at 37°C. The medium was then removed and the cultures infected  
14 with 66,000 pfu of RSV for two hours at 37°C in presence of SB105A10. Cultures were then  
15 washed apically with 100 µl of medium, placed at 37°C and fed each day via the basolateral surface  
16 with 0.9 ml medium. To harvest the virus, 100 µl medium was added to the apical surface and cells  
17 then allowed to equilibrate for 30 minutes at 37°C. The suspension was then collected and stored at  
18 -80°C until viral titres were determined by plaque assay in Hep-2 cell monolayers as described  
19 above. The viral collection was performed sequentially on the same wells of cells on each day post-  
20 infection.

21 **Detection of RSV in EpiAirway™ Tissue by immunohistochemistry.** RSV in EpiAirway™  
22 cultures was detected immunohistochemically using a specific mouse monoclonal antibody against  
23 RSV subtypes A and B (AbCam, Cambridge, UK). Briefly, EpiAirway™ tissue cultures were fixed  
24 in buffered formalin and, properly oriented, embedded in paraffin together with adherent collagen  
25 membranes. Immunohistochemical sections were processed for antigen retrieval in citrate buffer  
26 using a dedicated pressure cooker (1 cycle for 5 minutes at 125°C, followed by 10 seconds at 90°C)

1 in parallel with sections stained with conventional haematoxylin and eosin. Following incubation  
2 with the primary antibody (1:500 dilution), the reaction was visualised using a biotin-free polymer-  
3 conjugated secondary antibody (Envision, Dako, Glostrup, Denmark). In the presence of a positive  
4 reaction, the antibody showed cytoplasmic and nuclear immunoreactivity, mostly recognisable in  
5 the cells of the superficial layers. Several sections were analysed for each experimental condition.

6 **Statistical analysis.** Inhibition of infectivity and formation of syncytia in the presence and absence  
7 of the putative antiviral compounds were compared using Student's *t* tests. Results are expressed as  
8 means  $\pm$  1 standard deviation, as noted in the figure legends. *P* values  $\leq$  0.05 were considered as  
9 significant.

10

## 1 RESULTS

2

3 **Screening of a minilibrary of linear, dimeric and dendrimeric peptides for RSV-antiviral**  
4 **activity.** In the search for RSV inhibitors, we screened a peptide minilibrary that was previously  
5 generated to identify HSPGs antagonists. The minilibrary was composed of nine tetrameric, dimeric  
6 or linear peptide derivatives containing clusters of basic amino acids that hold the potential to bind  
7 to the negatively charged sulphate and carboxyl groups of the glycosaminoglycan chains of HS. The  
8 minilibrary was evaluated for *in vitro* activity against RSV using an infectivity inhibition assay on  
9 Hep-2 cells. As reported in Figure 1, one dimeric peptide, SB056-dim5, and three tetrameric  
10 compounds, SB007-pyrE, SB105 and SB105-A10, exerted statistical significant inhibitory activity  
11 (80–100%) at a concentration of 33 µg/ml ( $P < 0.05$ ).

12 **Activity of hit compounds.** The ability of the four hit compounds to inhibit RSV infection was  
13 investigated further by generating dose-response curves for two cell lines commonly used in RSV  
14 studies: Hep-2 and A549. As shown in Table 1, the half maximal inhibitory concentrations ( $IC_{50}$ )  
15 for peptides SB056-dim5, SB007-pyrE and SB105 were determined to be between 1.1 and 4.4 µM,  
16 whereas SB105-A10 was found to potently block RSV infection in A549 and Hep-2 cells with  $IC_{50}$   
17 values equal to 0.25 and 0.35 µM, respectively. Moreover, RSV-specific immunostaining revealed  
18 the absence of any RSV antigen-positive cell in the cultures treated with the highest concentrations  
19 of SB105-A10, suggesting that the dendrimer inhibits RSV at an early step of the replication cycle  
20 (data not shown). The  $CC_{50}$  were above 20 µM for all compounds tested, indicating that the  
21 inhibitory activities observed were not due to cytotoxicity. Since SB105-A10 was the most active of  
22 the peptides tested, it was subjected to further investigations.

23 **Investigation of the SB105-A10 inhibitory mechanism.** To determine the step in which SB105-  
24 A10 interferes with the infection process of RSV, two types of assays were performed on Hep-2  
25 cells (see Materials and methods). In the “attachment assay”, increasing concentrations of SB105-  
26 A10 were preincubated with RSV at 4°C and the mixture then added to cooled cells for a further 2

1 hours of incubation at 4°C. It is important to note that this procedure allowed viral attachment to  
2 occur, but until the cells were washed twice (to remove unbound virus) and the temperature raised  
3 to 37°C, viral entry and infection could not proceed. Under these experimental conditions, SB105-  
4 A10 strongly inhibited the infectivity of bound virus to the cell surface ( $IC_{50}$  = 1.74  $\mu$ M, Figure  
5 2A). Surprisingly, when the amount of virus bound to cells in these experimental conditions was  
6 quantified by enzyme-linked immunosorbent assay (ELISA; see “binding assay” in materials and  
7 methods), we found that preincubation of the virus with SB105-A10 increased the amount of RSV  
8 bound to the surface of Hep-2 (Figure 2B); the bound virus was unable, however, to proceed with  
9 the infectious process, as previously demonstrated in the attachment assay. Under the same  
10 experimental conditions, heparin (a polyanionic molecule that binds to RSV preventing its  
11 interaction with the cell surface; 40) effectively reduced the amount of RSV bound to Hep-2 cells to  
12 almost background levels.

13 To investigate further the mechanism of action of SB105-A10, a “pre-attachment assay” was  
14 performed where cell monolayers were incubated with increasing concentrations of SB105-A10 for  
15 1 hour at 4°C to allow its interaction with the cell surface. After removal of unbound compound,  
16 cells were further incubated with RSV for 3 hours at room temperature, washed and shifted to 37 °C  
17 for 70 hours. Under these experimental conditions, SB105-A10 retained its capacity to inhibit RSV  
18 infection with an  $IC_{50}$  (0.37  $\mu$ M); a value that is even higher than that achieved in the attachment  
19 assay (Figure 2C). These results suggest that SB105-A10 exerts its inhibitory activity mainly by  
20 binding to the virus binding sites present on the cell surface (likely HSPGs), making them  
21 unavailable for productive binding to the virus.

#### 22 **SB105-A10-PEG-biotin peptide binds HSPGs on the surface of epithelial A549 and Hep2 cells.**

23 On the basis of the results and considerations reported above, we investigated the direct binding of  
24 SB105-A10 to cell surfaces. To this purpose, in a first set of experiments we evaluated the capacity  
25 of SB105-A10-PEG-biotin to bind to the surface of epithelial A549 and Hep2 cells and the possible  
26 involvement of HSPGs in such an interaction. As shown in Fig. 3A, SB105-A10-PEG-biotin

1 peptide binds to A549 and Hep2 cells in a dose-dependent manner with  $EC_{50}$  values between 80-  
2 220 nM and saturation binding values of about 1100 nM of the dendrimer in both cell lines. To  
3 evaluate the possible involvement of cell surface HSPGs in the cells' interaction with SB105-A10-  
4 PEG-biotin, different approaches were used. First, as shown in Fig. 3B, heparin, a structural  
5 analogue of the saccharidic chains of HSPGs, was found to compete with SB105-A10-PEG-biotin  
6 for binding to the cell surface. Moreover, washing with 2.0 M NaCl, a treatment known to interfere  
7 with the binding of basic polypeptides to heparin/HSPGs (35), removed SB105-A10-PEG-biotin  
8 peptide from the cell surface. Finally, inhibiting the sulphation of HSPG saccharidic chains by  
9 treatment with sodium chlorate (38), as well as removing the saccharidic chains themselves by  
10 heparinase III, significantly reduced the capacity of both A549 and Hep2 cells to bind SB105-A10-  
11 PEG-biotin peptide.

12 **SB105-A10 inhibits syncytium formation.** Syncytia formation is a well known mechanism of cell-  
13 to-cell infection that contributes significantly to virus spread *in vivo*. To determine whether SB105-  
14 A10 prevents cell-to-cell spread of virus after infection, a syncytium formation assay was  
15 performed on infected Hep-2 cells. Increasing concentrations of the dendrimer were added to cells  
16 immediately after RSV adsorption, and monolayers were immunostained and examined for syncytia  
17 formation, as described in Materials and Methods. As shown in Fig. 4A, large syncytia were visible  
18 by RSV-specific immunostaining in untreated Hep-2 cells 72 hours post-infection. In contrast, the  
19 area of syncytia decreased in a dose-dependent manner in SB105-A10-treated cells and, at a  
20 concentration of 100  $\mu\text{g/ml}$ , singly infected cells were mainly seen. When used at high  
21 concentrations, SB105-A10 not only decreases the area of the syncytia, but it also reduces the  
22 number of syncytia present and even the number of infected cells. Similar results were obtained  
23 using A549 cells (Fig. 4B).

24 **Antiviral activity of SB105A10 in EpiAirway™ Tissue.** The EpiAirway™ System consists of  
25 human-derived tracheal/bronchial epithelial cells grown on a collagen coated membrane to form a  
26 highly differentiated, organotypic model with many of the same features of respiratory mucosa; thus



1 providing a useful *in vitro* means to assess respiratory infections, such as RSV infection. We  
2 assessed the effect of SB105A10 on RSV infection in EpiAirway™ cultures by measuring the titre  
3 of virus emerging from the apical surface. At 72 hours post-infection, the virus titre of untreated  
4 control tissue was  $1.05 \times 10^5$  pfu/ml whereas the titre of the tissue treated with 10 µg/ml of SB105-  
5 A10 was  $1.19 \times 10^4$  pfu/ml. Thus the compound inhibited the viral titer by 88.7%.

6 To reinforce this finding, the same tissues were fixed immediately after the virus harvest at 72 hours  
7 post-infection and subjected to immunohistochemistry using an RSV specific monoclonal antibody.  
8 All the sections derived from the infected tissue consistently showed the presence of cells  
9 expressing the RSV antigen in the upper cellular layer (Fig. 5B). The signal was considered as  
10 specific since no RSV positive cells could be observed in sections from uninfected tissue (Fig.5A).  
11 The sections from infected tissues that had been treated with SB105-A10 showed either no signal or  
12 single RSV positive cells (Fig. 5C).

13 Since EpiAirway™ Tissue is ideally suited for toxicology studies, we also exploited it to evaluate  
14 the irritation and inflammatory potential of SB105A10. Briefly, SB105A10 (100 µg/ml) was  
15 applied to the apical surface at the air-tissue interface of tissues for 0.5, 1, 4 and 18 hours at 37°C  
16 and tissues were then analysed for: i) the reduction of tetrazolium salt (MTT), to study the  
17 metabolic activity of the living cells; ii) lactate dehydrogenase (LDH) release, to measure the  
18 accumulation of dead cells; and iii) the release of IL-8, to evaluate inflammatory activation of cells  
19 (see Materials and Methods for further details). As reported in Table 2, SB105A10 was not  
20 cytotoxic and the time required to reduce tissue viability to 50% (ET<sub>50</sub>) was greater than 18 hours.  
21 No significant difference in the release of the cytoplasmic enzyme LDH was observed between  
22 SB105-A10-treated and untreated tissues. Finally, our results indicate that human-derived  
23 tracheal/bronchial epithelial cells exposed to SB105A10 do not exhibit significant differences in  
24 levels of the pro-inflammatory cytokine IL-8 (Table 2) compared to untreated samples.

## 1 **DISCUSSION**

2 Many viruses exploit HSPGs as co-receptors, or even entry-receptors, to infect target cells. On the  
3 molecular level, the sulphated groups on HSPGs interact with clusters of basic amino acids (also  
4 defined as ‘heparin binding domains’, HBDs) present within proteins on the virus’s surface that act  
5 as determinants of infectivity (37). The dependency of infection upon HSPGs is common among  
6 viruses, making it an attractive target for the development of novel antiviral drugs. So far, this  
7 approach has mainly been tackled using polyanionic/HSPG-antagonist heparin-like compounds that  
8 bind to viruses and thus sequester the infectious agents within the extracellular environment (37,  
9 46). Conversely, polycationic/HBD-mimicking compounds able to bind to mask HSPGs, thus  
10 hampering virus attachment, have been largely neglected.

11 In the present study, we screened a minilibrary of linear, dimeric and tetrameric peptides containing  
12 clusters of basic amino acids in order to identify novel inhibitors of RSV infection. Four hit  
13 compounds were identified, and the dendrimer SB105-A10 emerged as being the most potent  
14 inhibitor with IC<sub>50</sub> values equal to 0.35  $\mu$ M and 0.25  $\mu$ M when measured in Hep-2 and A549 cells,  
15 respectively. Of note, SB105-A10 prevented RSV infection when added before the viral inoculum  
16 (see the results of the pre-attachment assay, Fig.2C), but it was also able to reduce the cell-to-cell  
17 spread of the virus when added post-infection (Fig. 4).

18 To date, SB105-A10 has been found to be active against three DNA viruses, namely HSV, HCMV  
19 and HPV (10, 28, 29). RSV (an enveloped RNA virus) shares with these viruses the capacity to  
20 bind heparin and the requirement to interact with HSPGs on the target cell surface for infection. The  
21 binding of the aforementioned viruses to heparin/HSPGs depends on the presence of HBDs in their  
22 surface proteins (37). The peptide that functionalises SB105-A10 contains the following stretch of  
23 basic amino acids ASLRVRIKK, which mimics the HBD of RSV envelope glycoproteins G and F.  
24 Accordingly, it has been demonstrated that SB105-A10 binds to heparin immobilised to a BIAcore  
25 sensor chip – a model which allows protein interactions with cell surface HSPGs to be studied in a  
26 “cell-free” system (10). Moreover, the results here reported demonstrate that the binding of SB105-

1 A10 to two different epithelial cell types mainly depends on HSPGs. These findings suggest that  
2 SB105-A10 exerts its antiviral activity by competing with glycoprotein G or F for binding to cell  
3 surface HSPGs. This hypothesis is further sustained by the observations that SB105-A10 effectively  
4 blocks the binding of other HSPG-dependent viruses (including HPV, HSV and HCMV), but does  
5 not exert any antiviral activity against HSPG-independent viruses (including rotavirus and  
6 adenovirus) (10, 28, 29).

7 Despite the features of SB105-A10 described above and its effective capacity to inhibit RSV  
8 infection in the attachment assay (see Fig. 2A), our binding assay revealed that SB105-A10 actually  
9 increases the number of virus particles that bind to the cell surface (see Fig. 2B). We can  
10 hypothesise that, due to its dendrimeric structure and multivalent binding nature, SB105-A10 sets  
11 up cross-binding interactions between cell surface HSPGs and RSV, generating the “abortive”  
12 binding of large macromolecule complexes to the cell surface that hamper the capacity of HSPGs to  
13 mediate infection.

14 As mentioned above, the interaction of viral HBD with negatively charged sulfated/carboxyl groups  
15 of HSPGs is one of the major targets of antiviral research. As a consequence, HSPG-antagonist  
16 sulphated polysaccharides (i.e. polyanionics) have been largely investigated as antivirals for  
17 decades (37). In contrast, polycationic/HBD-mimicking compounds that bind HSPGs (like SB105-  
18 A10 studied here) have received the little research attention to date. Nevertheless, several important  
19 features render this latter class of compounds (i.e. HSPG-binding/HBD-mimicking compounds),  
20 and in particular SB1015-A10, highly attractive molecules for further development: first, while  
21 polyanionic/HSPG-antagonists are directed at the virus, which hold the capacity to develop  
22 resistance to the drug, compounds like SB105-A10 target a cellular component, making the  
23 emergence of resistant viruses less likely. Secondly, polyanionic/HSPG-antagonists have a narrow  
24 therapeutic window, acting only in the presence of viruses. Moreover, as they exert their action  
25 within body fluids, they can be rapidly cleared. In contrast, SB1015-A10 acts by binding to cell  
26 surface HSPGs, an interaction that is known to be long-lasting (35) and that thereby protects bound  
27 molecules from inactivation processes (7), suggesting that, once administered, SB1015-A10

1 maintains its antiviral activity for prolonged periods of time. Indeed, the present study found that  
2 even if SB1015-A10 was administered to cells prior to the RSV challenge, its antiviral effect was  
3 effectively maintained.

4 On the other hand, both polyanionic/HSPG-antagonists and polycationic/HBD-mimicking  
5 compounds share common drawbacks, such as the potential to interfere with physiological cellular  
6 signalling cascades and their consequent cellular responses. Indeed, HSPGs interact with a variety  
7 of physiological extracellular ligands, participating in an array of cellular events during cell  
8 adhesion, migration, proliferation and differentiation (1, 34, 45). This issue should be carefully  
9 addressed in preclinical studies before candidating SB105-A10 as an antiviral for the prevention  
10 and/or control of RSV infections.

11 With regard to the potential administration of SB105-A10 as an aerosolized formulation, we  
12 assessed its biocompatibility on human-derived tracheal/bronchial epithelial cells cultured to form a  
13 pseudo-stratified, highly differentiated model (EpiAirway<sup>TM</sup>) which closely resembles the epithelial  
14 tissue of the respiratory tract. This model system avoids species extrapolation and the use of animal  
15 models at the early, preclinical phase of development. The results demonstrate that SB105-A10 is  
16 well tolerated by the tissue and we observed no signs of cytotoxic or pro-inflammatory effects with  
17 a 100 µg/ml dosage. Besides biocompatibility, we also assessed the antiviral activity of SB105-A10  
18 on RSV-infected EpiAirway<sup>TM</sup> tissues. This model system provides a better simulation of the  
19 human respiratory tract than the cell monolayers used in standard antiviral assays. It carries the  
20 same cell type composition and polarity, mucus secreting function and mucociliary movements as  
21 the airway epithelium *in vivo*. Moreover, the HSGP composition and expression level *in vivo* are  
22 expected to be well duplicated in the EpiAirway<sup>TM</sup> tissue. Both the virus yield assays and the  
23 immunohistochemistry analysis of histological cross-sections showed a clear antiviral activity of  
24 SB105-A10 in the EpiAirway<sup>TM</sup> tissue at a dose of 10 µg/ml, indicating that this inhibitory strategy  
25 may well be effective *in vivo*.

26 In conclusion, the biocompatibility and confirmed antiviral activity of SB105-A10 in an *in vitro*  
27 model that closely resembles the epithelial tissue of the human respiratory tract indicate the

1 compound as a good candidate antiviral treatment for aerosol delivery. Studies are ongoing in  
2 animal models to assess the clinical potential of this inhibitor.

3

#### 4 **Acknowledgements**

5 This work was supported by grants from Ministero Istruzione Università e Ricerca (PRIN 2008) and  
6 Istituto Superiore di Sanità (AIDS Project) to DL and MR. We are grateful to Spider Biotech s.r.l.  
7 for providing the peptide minilibrary. AG and GP are cofounders of Spider Biotech. The other  
8 Authors declare no conflict of interest.

9

10

1 **REFERENCES**

- 2 1. **Bishop JR, Schuksz M, Esko JD.** 2007. Heparan sulphate proteoglycans fine-tune mammalian  
3 physiology. *Nature.* **446**:1030-1037.
- 4 2. **Boas U, Heegaard PM.** 2004. Dendrimers in drug research. *Chem Soc Rev.* **33**:43-63.
- 5 3. **Bourgeois C, Bour JB, Lidholt K, Gauthray C, Pothier P.** 1998. Heparin-like structures on  
6 respiratory syncytial virus are involved in its infectivity in vitro. *J. Virol.* **72**:7221-7227.
- 7 4. **Castilow EM, Varga SM.** 2008. Overcoming T cell-mediated immunopathology to achieve  
8 safe RSV vaccination. *Future Virol.* **3**:445-454.
- 9 5. **Cloninger MJ.** 2002. Biological applications of dendrimers. *Curr. Opin. Chem. Biol.* **6**:742-  
10 728.
- 11 6. **Collins PL, Crowe JE Jr.** 2007. Respiratory syncytial virus and Metaneumovirus. p 1601–  
12 1646. *In* Knipe DM, Howley PM (eds) *Fields Virology*, 5th edition. Lippincott Williams and  
13 Wilkins, Philadelphia.
- 14 7. **Coltrini D, Rusnati M, Zoppetti G, Oreste P, Isacchi A, Caccia P, Bergonzoni L, Presta M.**  
15 1993. Biochemical bases of the interaction of human basic fibroblast growth factor with  
16 glycosaminoglycans. New insights from trypsin digestion studies. *Eur. J. Biochem.* **214**:51-58.
- 17 8. **Corsello G.** 2007. Bronchiolitis: the new American Academy of Pediatrics guidelines. *J.*  
18 *Chemother.* **19**:12-14.
- 19 9. **Crim RL, Audet SA, Feldman SA, Mostowski HS, Beeler JA.** 2007. Identification of linear  
20 heparin-binding peptides derived from human respiratory syncytial virus fusion glycoprotein  
21 that inhibit infectivity. *J Virol.* **81**:261-271.
- 22 10. **Donalisio M, Rusnati M, Civra A, Bugatti A, Allemand D, Pirri G, Giuliani A, Landolfo S,**  
23 **Lembo D.** 2010. Identification of a dendrimeric heparan sulfate-binding peptide that inhibits  
24 infectivity of genital types of human papillomaviruses. *Antimicrob. Agents Chemother.*  
25 **54**:4290-4299.

- 1 11. **Empey KM, Peebles RS, Kolls JK.** 2010. Pharmacologic advances in the treatment and  
2 prevention of respiratory syncytial virus. *Clin Infect Dis.* **50**:1258-1267.
- 3 12. **Ernst S, Langer R, Cooney CL, Sasisekharan R.** 1995. Enzymatic degradation of  
4 glycosaminoglycans. *Crit. Rev. Biochem. Mol. Biol.* **30**:387–444.
- 5 13. **Escribano-Romero E, Rawling J, García-Barreno B, Melero JA.** 2004. The soluble form of  
6 human respiratory syncytial virus attachment protein differs from the membrane-bound form in  
7 its oligomeric state but is still capable of binding to cell surface proteoglycans. *J. Virol.*  
8 **78**:3524-3532.
- 9 14. **Falsey AR, Formica MA, Hennessey PA, Criddle MM, Sullender WM, Walsh EE.** 2006.  
10 Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease.  
11 *Am. J. Respir. Crit. Care Med.* **173**:639-643.
- 12 15. **Feldman SA, Audet S, Beeler JA.** 2000. The fusion glycoprotein of human respiratory  
13 syncytial virus facilitates virus attachment and infectivity via an interaction with cellular  
14 heparan sulfate. *J. Virol.* **74**:6442-6447.
- 15 16. **Feldman SA, Hendry RM, Beeler JA.** 1999. Identification of a linear heparin binding domain  
16 for human respiratory syncytial virus attachment glycoprotein G. *J. Virol.* **73**:6610-6617.
- 17 17. **Gias E, Nielsen SU, Morgan LAF, Toms GL.** 2008. Purification of human respiratory  
18 syncytial virus by ultracentrifugation in iodixanol density gradient. *Journal of Virological*  
19 *Methods.* **147**:328-332.
- 20 18. **Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P,**  
21 **Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P.** 2009. The burden of  
22 respiratory syncytial virus infection in young children. *N. Engl. J. Med.* **360**:588-598.
- 23 19. **Hallak LK, Collins PL, Knudson W, Peebles ME.** 2000. Iduronic acid-containing  
24 glycosaminoglycans on target cells are required for efficient respiratory syncytial virus  
25 infection. *Virology.* **271**:264-275.


- 1 20. **Hallak LK, Spillmann D, Collins PL, Peeples ME.** 2000. Glycosaminoglycan sulfation  
2 requirements for respiratory syncytial virus infection. *J. Virol.* **74**:10508-10513.
- 3 21. **Harris J, Werling D.** 2003. Binding and entry of respiratory syncytial virus into host cells and  
4 initiation of the innate immune response. *Cell. Microbiol.* **5**:671-680.
- 5 22. **Hsiung GD.** 1994. Virus assay, neutralization test, and antiviral assay, p.46. *In* V. F. Chan (ed.)  
6 Hsiung's diagnostic virology. Yale University Press, New Haven, CT.
- 7 23. **Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M,**  
8 **O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC,**  
9 **Young JF.** 1997. Development of a humanized monoclonal antibody (MEDI-493) with potent  
10 in vitro and in vivo activity against respiratory syncytial virus. *J. Infect. Dis.* **176**:1215-1224.
- 11 24. **Karger A, Schmidt U, Buchholz UJ.** 2001. Recombinant bovine respiratory syncytial virus  
12 with deletions of the G or SH genes: G and F proteins bind heparin. *J. Gen. Virol.* **82**:631-640.
- 13 25. **Kimura K, Ishioka K, Hashimoto K, Mori S, Suzutani T, Bowlin TL, Shigeta S.** 2004.  
14 Isolation and characterization of NMSO<sub>3</sub>-resistant mutants of respiratory syncytial virus.  
15 *Antiviral Res.* **61**:165-171.
- 16 26. **Krusat T, Strecker HJ.** 1997. Heparin-dependent attachment of respiratory syncytial virus  
17 (RSV) to host cells. *Arch. Virol.* **142**:1247-1254.
- 18 27. **Leader S, Kohlhase K.** 2002. Respiratory syncytial virus-coded pediatric hospitalizations,  
19 1997 to 1999. *Pediatr Infect. Dis. J.* **21**:629-632.
- 20 28. **Luganini A, Giuliani A, Pirri G, Pizzuto L, Landolfo S, Gribaudo G.** 2010. Peptide-  
21 derivatized dendrimers inhibit human cytomegalovirus infection by blocking virus binding to  
22 cell surface heparan sulfate. *Antiviral Res.* **85**:532-540.
- 23 29. **Luganini A, Nicoletto SF, Pizzuto L, Pirri G, Giuliani A, Landolfo S, Gribaudo G.** 2011.  
24 Inhibition of herpes simplex virus type 1 and type 2 infections by peptide-derivatized  
25 dendrimers. *Antimicrob. Agents Chemother.* **55**:3231-3239.



- 1 30. **Magro, M, Andreu D, Gómez-Puertas P, Melero JA, Palomo C.** 2010. Neutralization of  
2 human respiratory syncytial virus infectivity by antibodies and low-molecular-weight  
3 compounds targeted against the fusion glycoprotein. *J. Virol.* **84**:7970-7982.
- 4 31. **Martínez I, Melero JA.** 2000. Binding of human respiratory syncytial virus to cells:  
5 implication of sulfated cell surface proteoglycans. *J. Gen. Virol.* **81**:2715-2722.
- 6 32. **Meissner HC, Rennels MB, Pickering LK, Hall CB.** 2004. Risk of severe respiratory  
7 syncytial virus disease, identification of high risk infants and recommendations for prophylaxis  
8 with palivizumab. *Pediatr. Infect. Dis. J.* **23**:284-285.
- 9 33. **Pelletier AJ, Mansbach JM, Camargo CA Jr.** 2006. Direct medical costs of bronchiolitis  
10 hospitalizations in the United States. *Pediatrics.* **118**:2418-2243.
- 11 34. **Perrimon N, Bernfield M.** 2000. Specificities of heparan sulphate proteoglycans in  
12 developmental processes. *Nature.* **404**:725-728.
- 13 35. **Rusnati, M, Urbinati C, Presta M.** 1993. Internalization of basic fibroblast growth factor  
14 (bFGF) in cultured endothelial cells: role of the low affinity heparin-like bFGF receptors. *J.*  
15 *Cell. Physiol.* **154**:152-161.
- 16 36. **Rusnati M, Urbinati C.** 2009. Polysulfated/sulfonated compounds for the development of  
17 drugs at the crossroad of viral infection and oncogenesis. *Curr. Pharm. Des.* **15**:2946-2957.
- 18 37. **Rusnati M, Vicenzi E, Donalisio M, Oreste P, Landolfo S, Lembo D.** 2009. Sulfated K5  
19 *Escherichia coli* polysaccharide derivatives: A novel class of candidate antiviral microbicide.  
20 *Pharmacol. Ther.* **123**:310-322.
- 21 38. **Safaiyan F, Kolset SO, Prydz K, Gottfridsson E, Lindahl U, Salmivirta M.** 1999. Selective  
22 effects of sodium chlorate treatment on the sulfation of heparan sulfate. *J. Biol. Chem.*  
23 **274**:36267-36273.
- 24 39. **Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ.** 2001. Bronchiolitis-  
25 associated mortality and estimates of respiratory syncytial virus-associated deaths among US  
26 children, 1979-1997. *J Infect. Dis.* **183**:16-22.

- 1 40. **Shukla D, Spear PG.** 2001. Herpesviruses and heparan sulfate: an intimate relationship in aid  
2 of viral entry. *J. Clin. Invest.* **108**:503–510.
- 3 41. **Stewart DL.** 2010. Studies recommending palivizumab restriction have serious deficiencies. *J.*  
4 *Manag. Care Pharm.* **16**:509-511.
- 5 42. **Storey S.** 2010. Respiratory syncytial virus market. *Nat. Rev. Drug Discov.* **9**:15-16.
- 6 43. **Tayyari F, Marchant D, Moraes TJ, Duan W, Mastrangelo P, Hegele RG.** 2011.  
7 Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. *Nat. Med.*  
8 **17**:1132-1135.
- 9 44. **Techaarpornkul S, Collins PL, Peeples ME.** 2002. Respiratory syncytial virus with the fusion  
10 protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for  
11 attachment than complete virus. *Virology.* **294**:296-304.
- 12 45. **Tumova S, Woods A, Couchman JR.** 2000. Heparan sulfate proteoglycans on the cell surface:  
13 versatile coordinators of cellular functions. *Int. J. Biochem. Cell. Biol.* **32**:269-288.
- 14 46. **Urbinati C, Chiodelli P, Rusnati M.** 2008. Polyanionic drugs and viral oncogenesis: a novel  
15 approach to control infection, tumor-associated inflammation and angiogenesis. *Molecules.*  
16 **13**:2758-2785.
- 17 47. **Weisman LE.** 2009. Respiratory syncytial virus (RSV) prevention and treatment: past, present,  
18 and future. *Cardiovasc. Hematol. Agents Med. Chem.* **7**:223-233.
- 19 48. **Welliver RC.** 2010. Pharmacotherapy of respiratory syncytial virus infection. *Curr. Opin.*  
20 *Pharmacol.* **10**:289-293.
- 21 49. **World Health Organization.** 2009. Initiative for vaccine research (IVR). **Acute Respiratory**  
22 **Infections.** Geneva, Switzerland. [http://www.who.int/vaccine\\_research/diseases/ari/en/](http://www.who.int/vaccine_research/diseases/ari/en/).
- 23 50. **Wu P, Dupont WD, Griffin MR, Carroll KN, Mitchel EF, Gebretsadik T, Hartert TV.**  
24 2008. Evidence of a causal role of winter virus infection during infancy in early childhood  
25 asthma. *Am. J. Respir. Crit. Care Med.* **178**:1123-1129.




- 1 51. **Wu H, Pfarr DS, Losonsky GA, Kiener PA.** 2008. Immunoprophylaxis of RSV infection:
- 2     advancing from RSV-IGIV to palivizumab and motavizumab. *Curr. Top. Microbiol. Immunol.*
- 3     **317:103-123.**




**Figure 1. Screening of a peptide minilibrary against RSV.** Hep-2 cells were preincubated with compounds (33  $\mu\text{g/ml}$ ) for 45 minutes at 4°C before the addition of virus for 3 hours at room temperature. Cells were then washed to remove unbound virus and overlaid with 1.2% methylcellulose medium. Three days post-infection, cells were fixed and subjected to RSV-specific immunostaining. Plaques were counted and the percent inhibition of virus infectivity determined with respect to untreated control wells. The data represent the mean of at least three independent experiments. \*  $P < 0.05$ .

TABLE 1. Inhibition of RSV infection of Hep-2 and A549 cells by hit compounds.





Compound	Hep-2 cells		A549 cells	
	IC <sub>50</sub> (μM)	CC <sub>50</sub> (μM)	IC <sub>50</sub> (μM)	CC <sub>50</sub> (μM)
SB056-dim5	4.4 ± 2.2	>20	3.2 ± 2.0	>20
SB007-pyrE	1.19 ± 1.8	>20	2.4 ± 1.2	>20
SB105	2.8 ± 1.2	>20	3.0 ± 0.9	>20
SB105-A10	0.35 ± 0.1	>20	0.25 ± 0.1	>20



**Figure 2. Investigation of SB105-A10 antiviral mechanism in Hep-2 cells.** (A) Pre-attachment assay. Hep-2 cells were pretreated with increasing concentrations of SB105-A10 for 1 hour at 4°C, washed and then infected. Three days post-infection the cells were fixed, subjected to RSV-specific immunostaining and the plaques counted. (B and C) Quantification of virus binding to cells and infectivity in the presence of SB105-A10. RSV was added to cells for 2 hours at 4°C for preincubation in the absence or presence of SB105-A10. In the “attachment assay” (B), cells were shifted to 37°C and 72 hours post-infection subjected to RSV-specific immunostaining and the plaques counted. In the “binding assay” (C), the virus bound to cells was detected by enzyme-linked immunosorbent assay (ELISA) immediately after the removal of the virus inoculum. The results are given as the mean  $\pm$  standard deviation of triplicates.




**Figure 3. Binding of SB105-A10-PEG-biotin to HSPGs expressed at the surface of A549 and Hep2 epithelial cells.** Monolayers of A549 and Hep2 epithelial cells were incubated with increasing concentrations (A) or 220 nM (B) of SB105-A10-PEG-biotin peptide alone or in the presence of heparin (100  $\mu\text{g}/\text{ml}$ ) and washed with PBS containing 2 M NaCl. Alternatively, cell monolayers were pretreated with sodium chlorate (40 mM) or heparinase III (15 mU/ml) before incubation with SB105-A10-PEG-biotin. The amount of biotinylated SB105-A10 bound to cells was subsequently measured. Each point is the mean  $\pm$  SEM of 3-4 determinations performed in duplicate.

**A****B**




**Figure 4. Inhibition of RSV-induced syncytia formation by SB105-A10.** (A) Hep-2 cells and (B) A549 cells were infected with RSV in the absence of SB105-A10. The inoculum was removed at 3 hours post-infection and cells incubated in the presence of the following concentrations of SB105A10 in 1.2% methylcellulose medium: (b) 100  $\mu\text{g/ml}$ , (c) 66  $\mu\text{g/ml}$ , (d) 33  $\mu\text{g/ml}$ , (e) 3.6  $\mu\text{g/ml}$ . Formation of syncytia was assessed 72 hours after infection, as described in Materials and Methods. The histograms show the plaque area and the plaque count as a function of SB105-A10 concentration. The images in panels (C) and (D) show representative syncytia in Hep-2 and A549 cells, respectively. The results presented in this figure are representative of three independent experiments. \*  $P < 0.05$ ; \*\*  $P < 0.001$ .


**A**



**B**



**C**



**Figure 5. Reduction of RSV infected cells in EpiAirway tissue by SB105-A10.** Immunohistochemistry of control tissue (A), RSV-infected tissue (66,000 PFU) (B) and RSV-infected tissue treated with SB105-A10 (10 µg/ml) at 3 days post-infection (C), using a monoclonal antibody to RSV (brown signal). The pictures shown are representative of many analysed sections.

TABLE 2. Evaluation of the irritation potential of SB105-A10 (100 µg/ml) on the EpiAirway™ Tissue Model.

	<b>% of viability</b>	<b>LDH Release (Abs)</b>	<b>IL-8 Release (pg/ml)</b>
Untreated (30 min.)	100	0.25 ± 0.02	481.0 ± 19.0
SB105-A10 (30 min.)	98.2 ± 12.6	0.25 ± 0.08	489.5 ± 12.0
Untreated (1 hour)	100	0.23 ± 0.02	496.2 ± 11.0
SB105-A10 (1 hour)	84.9 ± 6.7	0.23 ± 0.01	491.5 ± 1.9
Untreated (4 hours)	100	0.22 ± 0.21	441.0 ± 39.3
SB105-A10 (4 hours)	95.3 ± 3.0	0.20 ± 0.02	477.6 ± 38.3
Untreated (18 hours)	100	0.17 ± 0.06	484.8 ± 25.1
SB105-A10 (18 hours)	94.7 ± 0.05	0.17 ± 0.03	476.0 ± 1.2